Lv11
70 积分 2024-03-07 加入
SGLT-2 inhibitors and euglycemic diabetic ketoacidosis/diabetic ketoacidosis in FAERS: a pharmacovigilance assessment
5小时前
待确认
GLP-1 receptor agonists and pancreatic cancer risk: target trial emulation using real-world data
3天前
已关闭
GLP-1 receptor agonists and pancreatic cancer risk: target trial emulation using real-world data
1个月前
已关闭
Sitagliptin, a dipeptidyl peptidase-4 inhibitor, suppresses CXCL5 and SDF-1 and does not accelerate intestinal neoplasia formation in ApcMin/+ mice fed a high-fat diet
1个月前
已完结
Anti-Tumor Necrosis Factor Therapy and the Risk of Gestational Diabetes in Pregnant Women with Inflammatory Bowel Disease
1个月前
已完结
Effect of frailty on effectiveness and safety of GLP-1 receptor agonists versus SGLT2 inhibitors in people with type 2 diabetes in Taiwan: a retrospective, nationwide, longitudinal study
1个月前
已完结
Glucagon-like peptide-1 (GLP-1) receptor agonists for weight management: A review for the gynecologic oncologist
2个月前
已完结
Effect of frailty on effectiveness and safety of GLP-1 receptor agonists versus SGLT2 inhibitors in people with type 2 diabetes in Taiwan: a retrospective, nationwide, longitudinal study
2个月前
已完结
Risk of hepatic events associated with use of sodium-glucose cotransporter-2 inhibitors versus glucagon-like peptide-1 receptor agonists, and thiazolidinediones among patients with metabolic dysfunction-associated steatotic liver disease
2个月前
已完结
Too good to be true: Are GLP-1 receptor agonists the new metformin?
2个月前
已完结
皖公网安备34019202002308
